Increased CD103−CD8+ TILs with TPEX phenotype replenish anti-tumor T cell pool in mismatch repair-proficient CRC
Open Access
- 3 November 2025
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (12) , 1-19
Abstract
While mismatch repair-deficient (dMMR) colorectal cancers (CRCs) exhibit strong immunogenicity and better response to immune checkpoint inhibitors, the more prevalent mismatch repair-proficient (pMMR) CRCs typically show poor T- cell infiltration and inferior outcomes. Profiling the limited tumor-infiltrating CD8 + T cells helps identify responders and guides new strategies to enhance their infiltration and function in pMMR CRC tumors. Our study reveals that the proportion and number of CD103 − CD8 + T (CD103N) cells are significantly increased in pMMR CRC tissue compared to adjacent non-tumor tissue. Distinguish from CD103 + CD8 + T (CD103P) cells with elevated T EX markers, these CD103N cells display a precursor exhausted T cells (T PEX ) phenotype with elevated stemness properties, reduced exhaustion markers, and retained functional capacity to secrete anti-tumor mediators. Moreover, CD103N cells in pMMR CRC shared a substantial number of identical TCR clonotypes with both CD103P cells in tumor and CD103N cell in peripheral blood. In dMMR CRC patients, enrichment of T PEX -like CD103N cells is associated with a favorable prognosis following anti-PD-1 therapy, suggesting their association with clinical outcome. Our findings identify an expanded population of CD103N cells exhibiting a T PEX phenotype with anti-tumor potential in pMMR CRC, highlighting their promise as therapeutic targets for recruitment into the tumor microenvironment to enhance the efficacy of immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (32370977)
This publication has 46 references indexed in Scilit:
- Tissue-resident memory CD103+CD8+ T cells in colorectal cancer: its implication as a prognostic and predictive liver metastasis biomarkerCancer Immunology, Immunotherapy, 2024
- Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancerCancer Cell, 2023
- Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancerCancer Cell, 2023
- The aryl hydrocarbon receptor cell intrinsically promotes resident memory CD8+ T cell differentiation and functionCell Reports, 2023
- The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodesCell, 2022
- Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancerCancer Cell, 2022
- Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancerCancer Immunology, Immunotherapy, 2022
- How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRCClinical Immunology, 2022
- Current status and future perspective of immune checkpoint inhibitors in colorectal cancerCancer Letters, 2021
- Higher numbers of T-bet+ intratumoral lymphoid cells correlate with better survival in gastric cancerCancer Immunology, Immunotherapy, 2012